Wexford Capital’s Pfizer PFE Stock Holding History

Wexford Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,309	Closed	-$341K	–	234
2023 Q2	$341K	Buy	+9,309	New	+$362K	0.07%	137
2020 Q3	–	Sell	-3,288	Closed	-$102K	–	245
2020 Q2	$102K	Buy	+3,288	New	+$112K	0.03%	141
2016 Q2	–	Sell	-168,037	Closed	-$4.72M	–	132
2016 Q1	$4.72M	Buy	168,037 +71,100	+73%	+$2.03M	0.92%	41
2015 Q4	$2.97M	Sell	96,937 -34,035	-26%	-$1.07M	0.7%	36
2015 Q3	$3.9M	Buy	+130,972	New	+$4.2M	0.75%	45
2014 Q4	–	Sell	-340,020	Closed	-$9.54M	–	94
2014 Q3	$9.54M	Buy	+340,020	New	+$9.54M	0.88%	15
2014 Q1	–	Sell	-53,417	Closed	-$1.55M	–	239
2013 Q4	$1.55M	Buy	+53,417	New	+$1.55M	0.13%	87

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wexford Capital's PFE Position: Q3 2023 in Review

Wexford Capital sold out of Pfizer (PFE) in Q3 2023, closing a stake of 9,309 shares — an estimated $341K sold.

Wexford Capital first reported a position in PFE in Q4 2013 and held it in 7 quarters. The position peaked at $9.54M in Q3 2014. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

Wexford Capital reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
Wexford Capital sold 9,309 Pfizer shares in Q3 2023, an estimated $341K.
Wexford Capital first reported a position in Pfizer in Q4 2013 and held it in 7 quarters.
Wexford Capital's Pfizer position peaked at $9.54M in Q3 2014.
2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Wexford Capital's 13F filing for Q3 2023, filed 14 Nov 2023.